Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 11/20 | 0.42 |
| ▸ | P2RX2 | Q9UBL9 | 11/20 | 0.42 |
| ▸ | WDR5 | P61964 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22588442 | 1.00 | P2RX3 (0.42) | P2RX3P2RX2WDR5MAPK1HSD17B10 | |
| SCHEMBL24620549 | 0.91 | GRM4 (0.44) | WDR5GRIN1GRIN2A | |
| SCHEMBL29808543 | 0.91 | GRM4 (0.44) | WDR5GRIN1GRIN2A | |
| SCHEMBL24620582 | 0.90 | GRM4 (0.44) | P2RX3P2RX2MAPK1HSD17B10 | |
| SCHEMBL22588976 | 0.89 | ALDH1A1 (0.46) | WDR5GRIN1GRIN2A | |
| SCHEMBL29808176 | 0.89 | ALDH1A1 (0.46) | WDR5GRIN1GRIN2A | |
| SCHEMBL22588864 | 0.87 | GRM4 (0.46) | WDR5 | |
| SCHEMBL29808192 | 0.87 | GRM4 (0.46) | WDR5 | |
| SCHEMBL22588777 | 0.84 | P2RX3 (0.41) | P2RX3P2RX2 | |
| SCHEMBL24620569 | 0.83 | EPHX2 (0.39) | P2RX3P2RX2WDR5GRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220220095-A1 | N-((HETEROARYL)METHYL)-1-TOSYL-1H-PYRAZOLE-3-CARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | H LUNDBECK AS (DK) | 2022-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220095-A1 | N-((HETEROARYL)METHYL)-1-TOSYL-1H-PYRAZOLE-3-CARBOXAMIDE DERIVATIVES AS Kv3 POTASSIUM CHANNEL ACTIVATORS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | KCNA3, KCNK3, KCND3 | P2RX3 117/4885P2RX2 196/4885WDR5 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.